BDI Pharma competitors

An intuitive leader who engenders a deep level of trust and loyalty while providing a clear vision and business strategy, with a proven track record in the pharmaceutical, generic, biotechnology and consumer product industries. Recognized for entrepreneurial leadership approach to turnaround and rapid growth environments, leveraging strategic creativity, consumer and professional customer insight, merger and acquisition experience and operational expertise, all driving shareholder value. Open to contract C-level and Board of Director positions.

John has over 20 years of healthcare experience with 10 years directly in the cancer field. He is a board member or trusted advisor on active investments in Cancer, Dermatology, Diabetes, Anatomical Pathology, Generic Pharmaceuticals, Nuclear Pharmaceuticals, Health Payments and Health Information Technology through Bioveda China Fund, Amorperum Health and with a small number of top tier Private Equity Healthcare Firms. He is very active in board roles with a variety of healthcare companies in Israel, China, India and the US. Some of his past boards include Prodigy Health, which sold to Aetna (NYSE:AET) , and CITIC Pharmaceuticals, which sold to Shanghai Pharmaceuticals (SH:601607). Previously, John was the CEO of Oncology Therapeutics Network, which sold to McKesson, President of Oncology Services at Bristol Myers Squibb, and a Vice President at McKesson. He was a co- founder of Cancer Centers of Excellence and an early investor in Oncology Molecular Imaging. John studied economics and physics at University of California at Davis and has a Bachelor of Science from University of the State of New York. John served for 12 years in the United States Air Force and Air National Guard. He is currently a member of YPO and is active with the Wounded Warrior Project.

Stephen J. Farr, Ph.D. is one of our co-founders and has served as our President and as a member of our board of directors since August 2006. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He is a fellow of the American Association of Pharmaceutical Scientists and visiting Associate Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.

J.D. Weir is a Chief Executive Officer at PRIMUS PHARMACEUTICALS INC and is based in United States.

Patrick Schmidt is a President/CEO at FFF Enterprises Inc.

Experienced Chief Executive Officer with a demonstrated history of working in the aesthetic, health care, and pharmaceutical industries. Strong legal and business professional skilled in Strategic Planning, Enhanced Valuation Strategies, M&A Activities, Intellectual Property and Brand Protection and Medical Compliance.